A practical reference on somatotroph: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-06 and is reviewed periodically as new material appears.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Removal of the Wall began on the evening of 9 November 1989 and continued over the following days and weeks, with people nicknamed Mauerspechte (wallpeckers) using various tools to chip off souvenirs, demolishing lengthy parts in the process, and creating several unofficial border crossings. In the season holidays this became a sort of international action. People from all over the western world went to West Berlin and local youth provided a range of appropriate demolition tools. Television coverage of citizens demolishing sections of the Wall on 9 November was soon followed by the East German regime announcing ten new border crossings, including the historically significant locations of Potsdamer Platz, Glienicker Brücke, and Bernauer Straße. Crowds gathered on both sides of the historic crossings waiting for hours to cheer the bulldozers that tore down portions of the Wall to reconnect the divided roads. While the Wall officially remained guarded at a decreasing intensity, new border crossings continued for some time. Initially the East German Border Troops attempted repairing the damage done by the "wallpeckers"; gradually these attempts ceased, and guards became laxer, tolerating the increasing demolitions and "unauthorized" border crossing through the holes.
On 15 October, Hezbollah launched five anti-tank missiles towards northern Israel killing one civilian and injuring three others in Shtula. UNIFIL said that their headquarters in Naqoura in southern Lebanon was hit by rocket fire with no casualties reported. Lieutenant Amitai Granot, commander of the 75th Battalion of the IDF's Golan Brigade and son of Rabbi Tamir Granot, was killed in a missile attack on an IDF post bordering Lebanon. On 13 October, while a group of Reuters, AFP and Al Jazeera journalists were transmitting a live video feed of an IDF outpost in Aalma ech Chaab, two tank rounds fired directly hit the group. The first killed Reuters photojournalist Issam Abdallah. The second strike was much more powerful and ignited the Al Jazeera vehicle, a white Toyota, which Al Jazeera journalists Carmen Joukhadar and Elie Brakhya, as well as their AFP colleague Dylan Collins were standing next to. Reuters photographer Christina Assi was also critically injured. The Lebanese Army has said the IDF fired the missile that killed Abdallah. Another Reuters reporter at the scene said Abdallah was killed by projectiles fired from the direction of Israel. His last post on Instagram, posted a week before he was killed, was a photograph of Shireen Abu Akleh, a Palestinian journalist for Al Jazeera Arabic who had been killed by Israel in 2022. On 16 October, Amnesty International reported that the IDF fired white phosphorus shells into Dhayra, hospitalizing nine civilians and setting fire to civilian objects.
The Swiss company GlycArt Biotechnology developed a system using CHO cells, where the cells were engineered to overexpress an enzyme called GnTIII. The effect of this overexpression is to block the formation of fucosylated oligosaccharides on the expressed antibodies. This technology was first reported in 1999 and was the basis of GlycArt Biotechnology. Roche acquired GlycArt in 2005 in order to acquire technology to afucosylate antibodies. GlycArt Biotechnology had been founded in 2000 as a spin-out company of the Swiss Federal Institute of Technology in Zurich. The first commercial product from the GlycArt acquisition was obinutuzumab, which as Gazyva gained FDA approval in November 2013 for the treatment of chronic lymphocytic leukemia. Kyowa Hakko Kirin's "Potelligent" platform uses a CHO cell line in which FUT8 has been knocked out, and which produces antibodies with little to no fucose in the Fc region. The company gained marketing approval in Japan in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform. The Company's technology was first reported in 2004.
Sources: en.wikipedia.org
==== Effects on plasticity ==== Activation of group 1 mGluRs are implicated in synaptic plasticity and contribute to both neurotoxicity and neuroprotection such as protection of the retina against NMDA toxicity, mentioned above. It causes a reduction in ZENK expression, which leads to myopia in chicken.
=== International System === The SI unit for elasticity and the elastic modulus is the pascal (Pa). This unit is defined as force per unit area, generally a measurement of pressure, which in mechanics corresponds to stress. The pascal and therefore elasticity have the dimension L−1⋅M⋅T−2. For most commonly used engineering materials, the elastic modulus is on the scale of gigapascals (GPa, 109 Pa).
Andean textiles Chakitaqlla Chinchaypujio District Chuspas Indigenous peoples in Argentina Indigenous peoples in Bolivia Indigenous peoples in Ecuador Indigenous peoples of Peru Inkarrí Kichwa Quechuan languages Secret of the Incas, movie with conversation and singing in Quechua Sumak kawsay Yanantin
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.